Evaluating the Safety and Tolerability and Determining the PK and PD of Single Dose UB-221 in Chronic Spontaneous Urticaria
NCT04175704
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
32
Enrollment
INDUSTRY
Sponsor class
Conditions
Chronic Idiopathic Urticaria
Interventions
DRUG:
UB-221
Sponsor
United BioPharma